Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PAC-MAN
NCT04148833Phase 3Unknown
- Sponsor
- Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
- Start
- Jun 2019
- Primary completion
- Aug 2020
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of LDE-paclitaxel in coronary artery disease (CAD) and atherosclerosis (2 arms), sponsored by Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo. Primary endpoints: Low Attenuation Plaque Volume coronary and Low Attenuation Plaque Volume aortic. Status: unknown.
02
Drugs
LDE-paclitaxel
03
Conditions
coronary artery disease (CAD)atherosclerosis
Beyond the preview
Go deeper on NCT04148833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04148833.